Challenges in adult vaccination

References

• Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282:20143085.
   PubMed Web of Science ®Google Scholar
• Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol. 2014;35:299–310.
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159–1169.
   PubMed Web of Science ®Google Scholar
• Pera A, Campos C, Lopez N, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82:50–55.
   PubMed Web of Science ®Google Scholar
• Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171.
   PubMed Web of Science ®Google Scholar
• LeBrasseur NK, Tchkonia T, Kirkland JL. Cellular senescence and the biology of aging, disease, and frailty. Nestle Nutr Inst Workshop Ser. 2015;83:11–18.
   PubMedGoogle Scholar
• Tan L. Adult vaccination: now is the time to realize an unfulfilled potential. Hum Vaccine Immunother. 2015;11:2158–2166.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Vaccine Action Plan 2011–2020. Available from: http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/. Accessed on 01 Aug 2017.
   Google Scholar
• van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med. 2013;369:2152–2158.
   PubMed Web of Science ®Google Scholar
• Bridges CB, Hurley LP, Williams WW, et al. Meeting the challenges of immunizing adults. Am J Prev Med. 2015;49:S455–S464.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, McGinnis JJ, Tan L, et al. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Primary Prevent. 2015;36:259–273.
   PubMed Web of Science ®Google Scholar
• Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2017. Am J Transplant. 2017;66:134–135.
   Google Scholar
• Kim DK, Riley LE, Harriman KH, et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older – United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:136–138.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. 2017. Available from: https://vaccine-schedule.ecdc.europa.eu/. Accessed on 01 Aug 2017.
   Google Scholar
• Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, etet al. Recommended immunization schedules for adults: clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother. 2016;12:1777–1794.
   PubMed Web of Science ®Google Scholar
• He W, Goodkind D, Kowal PR. United States Census Bureau. An aging world: 2015. Report No. P95/16-1. Washington, DC: U.S. Government Publishing Office; 2016. Available from: http://www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf. Accessed on 01 Aug 2017.
   Google Scholar
• United Nations. World Population Ageing 2015. Report No. ST/ESA/SER.A/390. New York: Department of Economic and Social Affairs, Population Division; 2015. Available from: http://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA-2015_Report.pdf. Accessed on 01 Aug 2017.
   Google Scholar
• Bloom DE, Chatterji S, Kowal P, et al. Macroeconomic implications of population ageing and selected policy responses. Lancet. 2015;385:649–657.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Anca I, Andre F, et al. Adult vaccination in 11 Central European countries – calendars are not just for children. Vaccine. 2012;30:1529–1540.
   PubMed Web of Science ®Google Scholar
• Jones DS, Podolsky SH, Greene JA. The burden of disease and the changing task of medicine. N Engl J Med. 2012;366:2333–2338.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Luca DL. 2016. The global demography of aging: facts, explanations, future. In: Piggott J, Woodland A, editors. Handbook of the economics of population aging. Oxford: Elsevier, 2016. p. 3–56.
   Google Scholar
• Gellin B, Landry S. The value of vaccines: our nation’s front line against infectious diseases. Clin Pharmacol Ther. 2010;88:580–581.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccine-preventable adult diseases. Available from: https://www.cdc.gov/vaccines/adults/vpd.html. Accessed on 01 Aug 2017.
   Google Scholar
• Poland GA, Belmin J, Langley J, et al. A global prescription for adult immunization: time is catching up with us. Vaccine. 2010;28:7137–7139.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66:1–28.
   PubMed Web of Science ®Google Scholar
• Annunziata K, Rak A, Del Buono H, et al. Vaccination rates among the general adult population and high-risk groups in the United States. PLoS One. 2012;7:e50553.
   PubMed Web of Science ®Google Scholar
• Kanitz EE, Wu LA, Giambi C, et al. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine. 2012;30:5222–5228.
   PubMed Web of Science ®Google Scholar
• Lu PJ, O’Halloran A, Williams WW, et al. National and state-specific shingles vaccination among adults aged >/=60 years. Am J Prev Med. 2017;52:362–372.
   PubMed Web of Science ®Google Scholar
• Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34:6681–6690.
   PubMed Web of Science ®Google Scholar
• Fine P, Eames K, Heymann DL. “Herd immunity: a rough guide”. Clin Infect Dis. 2011;52:911–916.
   PubMed Web of Science ®Google Scholar
• Krishnarajah G, Carroll C, Priest J, et al. Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations: analysis of claims-based databases, 2006-2010. Hum Vaccin Immunother. 2014;10:2460–2467.
   PubMed Web of Science ®Google Scholar
• Kristensen M, van Lier A, Eilers R, et al. Burden of four vaccine preventable diseases in older adults. Vaccine. 2016;34:942–949.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Portnoy A, Getaneh H, et al. Modeling the economic burden of adult vaccine-preventable diseases in the United States. Health Aff (Millwood). 2016;35:2124–2132.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med. 2008;121:S28–S35.
   PubMed Web of Science ®Google Scholar
• Lu PJ, O’Halloran A, Kennedy ED, et al. Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015. Vaccine. 2017;35:3104–3115.
   PubMed Web of Science ®Google Scholar
• MacDougall DM, Halperin BA, MacKinnon-Cameron D, et al. The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open. 2015;5:e009062.
   PubMed Web of Science ®Google Scholar
• Hurley LP, Lindley MC, Allison MA, et al. Primary care physicians’ perspective on financial issues and adult immunization in the Era of the Affordable Care Act. Vaccine. 2017;35:647–654.
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32:725–732.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374–1386.
   PubMed Web of Science ®Google Scholar
• Donken R, Bogaards JA, van der Klis FR, et al. An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. Hum Vaccin Immunother. 2016;12:1381–1393.
   PubMed Web of Science ®Google Scholar
• Bakker M, Bunge EM, Marano C, et al. Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccin. 2016;15:829–851.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Suryakiran P, et al. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccin Immunother. 2017;13:972–980.
   PubMed Web of Science ®Google Scholar
• Stoffel M, Lievens M, Dieussaert I, et al. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccin. 2003;2:9–14.
   PubMedGoogle Scholar
• Van der Wielen M, Van Damme P, Chlibek R, et al. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24:5509–5515.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW, Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922–928.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–909.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336–1344.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–835.
   PubMed Web of Science ®Google Scholar
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494–500.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14:428–436.
   PubMed Web of Science ®Google Scholar
• Ramasubramanian V. Pneumococcal Disease in Older Adults-An Overview. J Assoc Physicians India. 2015;63:7–12.
   PubMedGoogle Scholar
• Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med. 2015;7:281ps8.
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Gerontology. 2015;61:203–210.
   PubMed Web of Science ®Google Scholar
• Lang PO, Mendes A, Socquet J, et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64.
   PubMed Web of Science ®Google Scholar
• Dube E, Laberge C, Guay M, et al. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9:1763–1773.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rauber D, Betsch C, et al. Barriers of influenza vaccination intention and behavior – a systematic review of influenza vaccine hesitancy, 2005–2016. PLoS One. 2017;12:e0170550.
   PubMed Web of Science ®Google Scholar
• Bodeker B, Remschmidt C, Schmich P, et al. Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study. BMC Public Health. 2015;15:618.
   PubMed Web of Science ®Google Scholar
• Paterson P, Meurice F, Stanberry LR, et al. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34:6700–6706.
   PubMed Web of Science ®Google Scholar
• Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prev Med. 2014;69:224–234.
   PubMed Web of Science ®Google Scholar
• Eilers R, de Melker HE, Veldwijk J, et al. Vaccine preferences and acceptance of older adults. Vaccine. 2017;35:2823–2830.
   PubMed Web of Science ®Google Scholar
• Yeung MP, Lam FL, Coker R. Factors associated with the uptake of seasonal influenza vaccination in adults: a systematic review. J Public Health (Oxf). 2016;38:746–753.
   PubMed Web of Science ®Google Scholar
• Biasio LR. Vaccine hesitancy and health literacy. Hum Vaccin Immunother. 2017;13:701–702.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Del Giudice G, et al. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA. 2014;111:12288–12293.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupeze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccin. 2017;16:55–63.
   PubMed Web of Science ®Google Scholar
• Garcon N, Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother. 2017;13:19–33.
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19:2673–2680.
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol. 2015;386:151–180.
   PubMed Web of Science ®Google Scholar
• Domnich A, Arata L, Amicizia D, et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35:513–520.
   PubMed Web of Science ®Google Scholar
• Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–271.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32:1745–1753.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34:863–868.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–1032.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–645.
   PubMed Web of Science ®Google Scholar
• Bragazzi NL, Orsi A, Ansaldi F, et al. Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): an updated overview. Hum Vaccin Immunother. 2016;12:2616–2627.
   PubMed Web of Science ®Google Scholar
• Schneeberg A, Bettinger JA, McNeil S, et al. Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health. 2014;14:442.
   PubMed Web of Science ®Google Scholar
• Klett-Tammen CJ, Krause G, Seefeld L, et al. Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP). BMC Public Health. 2016;16:121.
   PubMed Web of Science ®Google Scholar
• Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among people >/= 50 years of age and its implications on immunization. Dermatol Online J. 2012;18:2.
   PubMedGoogle Scholar
• Joon Lee T, Hayes S, Cummings DM, et al. Herpes zoster knowledge, prevalence, and vaccination rate by race. J Am Board Fam Med. 2013;26:45–51.
   PubMed Web of Science ®Google Scholar
• MacDougall D, Halperin BA, MacKinnon-Cameron D, et al. Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: what Canadian health care providers know and need to know. Hum Vaccin Immunother. 2015;11:2167–2179.
   PubMed Web of Science ®Google Scholar
• Hurley LP, Bridges CB, Harpaz R, et al. Physician attitudes toward adult vaccines and other preventive practices, United States, 2012. Public Health Rep. 2016;131:320–330.
   PubMed Web of Science ®Google Scholar
• Jain A, van Hoek AJ, Boccia D, et al. Lower vaccine uptake amongst older individuals living alone: a systematic review and meta-analysis of social determinants of vaccine uptake. Vaccine. 2017;35:2315–2328.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Nowalk MP, Pavlik VN, et al. Using the 4 pillars practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial. BMC Infect Dis. 2016;16:623.
   PubMed Web of Science ®Google Scholar
• Nowalk MP, Lin CJ, Pavlik VN, et al. Using the 4 pillars practice transformation program to increase adult Tdap immunization in a randomized controlled cluster trial. Vaccine. 2016;34:5026–5033.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Brown AE, Pavlik VN, et al. Using the 4 pillars practice transformation program to increase pneumococcal immunizations for older adults: a cluster-randomized trial. J Am Geriatr Soc. 2017;65:114–122.
   PubMed Web of Science ®Google Scholar
• Baxter D. Approaches to the vaccination of pregnant women: experience from Stockport, UK, with prenatal influenza. Hum Vaccin Immunother. 2013;9:1360–1363.
   PubMed Web of Science ®Google Scholar
• Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711–1720.
   PubMed Web of Science ®Google Scholar
• Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;CD005050.
   PubMed Web of Science ®Google Scholar
• Moreno D, Barroso J, Garcia A. Vaccines for patients with COPD. Recent Pat Inflamm Allergy Drug Discov. 2015;9:23–30.
   PubMedGoogle Scholar
• Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging. 2014;9:433–441.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kao PF, Wu MY, et al. Influenza vaccination is associated with lower risk of acute coronary syndrome in elderly patients with chronic kidney disease. Medicine (Baltimore). 2016;95:e2588.
   PubMed Web of Science ®Google Scholar
• Ricci NA, Pessoa GS, Ferriolli E, et al. Frailty and cardiovascular risk in community-dwelling elderly: a population-based study. Clin Interv Aging. 2014;9:1677–1685.
   PubMed Web of Science ®Google Scholar
• Sreenivasan N, Basit S, Wohlfahrt J, et al. The short- and long-term risk of stroke after herpes zoster – a nationwide population-based cohort study. PLoS One. 2013;8:e69156.
   PubMed Web of Science ®Google Scholar
• Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601–610.
   PubMed Web of Science ®Google Scholar
• Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101:1738–1747.
   PubMed Web of Science ®Google Scholar
• Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. Acute cardiac injury events </=30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010-2012. BMC Cardiovasc Disord. 2015;15:109.
   PubMed Web of Science ®Google Scholar
• Chang TY, Chao TF, Liu CJ, et al. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm. 2016;13:1189–1194.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Mahimbo A, Moa AM, et al. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102:1953–1956.
   PubMed Web of Science ®Google Scholar
• Sung LC, Chen CI, Fang YA, et al. Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: a population-based cohort study. Vaccine. 2014;32:3843–3849.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J. 2017;38:334–337.
   PubMed Web of Science ®Google Scholar
• Fang YA, Chen CI, Liu JC, Sung LC. Influenza vaccination reduces hospitalization for heart failure in elderly patients with chronic kidney disease: a population-based cohort study. Acta Cardiol Sin. 2016;32:2908.
   Web of Science ®Google Scholar
• Mohseni H, Kiran A, Khorshidi R, et al. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J. 2017;38:326–333.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Udell JA, et al. Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. JACC Heart Fail. 2016;4:152–158.
   PubMed Web of Science ®Google Scholar
• Bhatt AS, DeVore AD, Hernandez AF, et al. Can vaccinations improve heart failure outcomes?: contemporary data and future directions. JACC Heart Fail. 2017;5:194–203.
   PubMedGoogle Scholar
• Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51:1007–1016.
   PubMed Web of Science ®Google Scholar
• Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:CD001390.
   PubMed Web of Science ®Google Scholar
• Lall D, Cason E, Pasquel FJ, et al. Effectiveness of influenza vaccination for individuals with chronic obstructive pulmonary disease (COPD) in low- and middle-income countries. COPD. 2016;13:93–99.
   PubMedGoogle Scholar
• Kostinov MP, Zhestkov AV, Protasov AD, et al. [New ideas on the therapeutic effect of a combination of vaccines against pneumococcal, Haemophilus influenzae type b infection, and influenza in patients with chronic obstructive pulmonary disease]. Ter Arkh. 2015;87:17–22.
   PubMed Web of Science ®Google Scholar
• Lau D, Eurich DT, Majumdar SR, et al. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax. 2013;68:658–663.
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13:53.
   PubMed Web of Science ®Google Scholar
• Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385:549–562.
   PubMed Web of Science ®Google Scholar
• Maciosek MV, Coffield AB, Flottemesch TJ, et al. Greater use of preventive services in U.S. health care could save lives at little or no cost. Health Aff (Millwood). 2010;29:1656–1660.
   PubMed Web of Science ®Google Scholar
• Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372:447–455.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33:1872–1894.
   PubMed Web of Science ®Google Scholar
• Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358:661–663.
   PubMed Web of Science ®Google Scholar
• Kottke TE, Pronk NP, Isham GJ. Does prevention save money? Health Aff (Millwood). 2009;28:1554–1555. author reply 5–6.
   PubMed Web of Science ®Google Scholar
• Goetzel RZ. Do prevention or treatment services save money? The wrong debate. Health Aff (Millwood). 2009;28:37–41.
   PubMed Web of Science ®Google Scholar
• Russell LB. Preventing chronic disease: an important investment, but don’t count on cost savings. Health Aff (Millwood). 2009;28:42–45.
   PubMed Web of Science ®Google Scholar
• Ethgen O, Cornier M, Chriv E, et al. The cost of vaccination throughout life: a western European overview. Hum Vaccin Immunother. 2016;12:2029–2037.
   PubMed Web of Science ®Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28:2356–2359.
   PubMed Web of Science ®Google Scholar
• Standaert B, Ethgen O, Emerson R, et al. Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn? Adv Ther. 2014;31:1095–1108.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14:245–252.
   PubMed Web of Science ®Google Scholar
• van der Putten IM, Paulus AT, Evers SM, et al. Identification and prioritization of the economic impacts of vaccines. Biomed Res Int. 2016;2016:6267343.
   PubMedGoogle Scholar
• Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30:337–353.
   PubMed Web of Science ®Google Scholar
• Standaert BA, Curran D, Postma MJ. Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Alloc. 2014;12:3.
   PubMed Web of Science ®Google Scholar